Form 8-K - Current report:
SEC Accession No. 0001437749-24-004267
Filing Date
2024-02-15
Accepted
2024-02-15 08:05:17
Documents
17
Period of Report
2024-02-15
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbla20240214_8k.htm   iXBRL 8-K 28617
2 EXHIBIT 99.1 ex_627012.htm EX-99.1 12802
7 ex_627012img001.jpg GRAPHIC 5293
  Complete submission text file 0001437749-24-004267.txt   186545

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pbla-20240215.xsd EX-101.SCH 3409
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbla-20240215_def.xml EX-101.DEF 11424
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbla-20240215_lab.xml EX-101.LAB 15310
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbla-20240215_pre.xml EX-101.PRE 11584
18 EXTRACTED XBRL INSTANCE DOCUMENT pbla20240214_8k_htm.xml XML 2828
Mailing Address 712 VISTA BLVD #305 WACONIA MN 55387
Business Address 712 VISTA BLVD #305 WACONIA MN 55387 9524791196
Panbela Therapeutics, Inc. (Filer) CIK: 0001029125 (see all company filings)

EIN.: 870543922 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39468 | Film No.: 24642183
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)